Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial

BMC Infectious Diseases

Chunhui Yang³  Gang Lu³  Juan Xie¹  Yu Zhang³  Lei Yan³  Wei Long²  Jianguo Tang³ 

[1] Department of Pulmonary Medicine, Shanghai Fifth People’s Hospital, Fudan University, Shanghai 200240, PR China;Department of Geriatrics, Shanghai Sixth People’s Hospital, Jiaotong University, Shanghai 200233, PR China;Department of Trauma-Emergency & Critical Care Medicine, Shanghai Fifth People’s Hospital, Fudan University, Shanghai 200240, PR China

关键词: Antibiotic;    Procalcitonin;    Asthma;   

Others  :  1135748
DOI  :  10.1186/1471-2334-13-596

 received in 2012-09-07, accepted in 2013-12-09,  发布年份 2013

【 摘 要 】

Background

This randomized controlled trial aimed to evaluate whether the serum procalcitonin (PCT) level can be utilized to guide the use of antibiotics in the treatment of acute exacerbations of asthma.

Methods

A total of 293 consecutive patients with suspected asthma attacks from February 2005 to July 2010 participated in this study. 225 patients completed the study. Serum PCT levels, and other inflammatory biomarkers of all patients were measured. In addition to the standard treatment, the control group received antibiotics according to the attending physicians’ discretions, while the patients in the PCT group were treated with antibiotics according to serum PCT concentrations. Antibiotics usage was strongly discouraged when the PCT concentration was below 0.1 μg/L; discouraged when the PCT concentration was between 0.1 μg/L and 0.25 μg/L; or encouraged when the PCT concentration was above 0.25 μg/L. The primary endpoint was the determination of antibiotics usage. The second endpoints included the diagnostic accuracy of PCT and other laboratory biomarkers the effectiveness of asthma control, secondary ED visits, hospital re-admissions, repeated needs for steroids or dosage increase, needs for antibiotics, WBC count, PCT levels and FEV1%.

Results

At baseline, two groups were identical regarding clinical, laboratory and symptom score. Probability of the antibiotics usage in the PCT group (46.1%) was lower than that in the control group (74.8%) (χ² = 21.97, p < 0.001. RR = 0.561, 95% CI 0.441-0.713). PCT and IL-6 showed good diagnostic significance for bacterial asthma (r = 0.705, p = 0.003). The degrees of asthma control in patients were categorized to three levels and were comparable between the two groups at the six weeks follow-up period (χ² = 1.62, p = 0.45). There were no significant difference regarding other secondary outcomes (p > 0.05).

Conclusions

The serum PCT concentration can be used to effectively determine whether the acute asthma patients have bacterial infections in the respiratory tract, and to guide the use of antibiotics in the treatment of acute asthma exacerbations, which may substantially reduce unnecessary antibiotic use without compromising the therapeutic outcomes.

Trial registration

ICTRP ChiCTR-TRC-12002534

【 授权许可】

   
2013 Tang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O'Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ: Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008, 31(1):143-178.
• [2]Vanderweil SG, Tsai CL, Pelletier AJ, Espinola JA, Sullivan AF, Blumenthal D, Camargo CA Jr: Inappropriate use of antibiotics for acute asthma in United States emergency departments. Acad Emerg Med 2008, 15(8):736-743.
• [3]Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY: Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006, 34(7):1996-2003.
• [4]Tang BM, Eslick GD, Craig JC, McLean AS: Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007, 7(3):210-217.
• [5]Müller F, Christ-Crain M, Bregenzer T, Krause M, Zimmerli W, Mueller B, Schuetz P, ProHOSP Study Group: Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010, 138(1):121-129.
• [6]Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B: Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 174(1):84-93.
• [7]Becker KL, Snider R, Nylen ES: Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008, 36(3):941-952.
• [8]Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, Huber P, Müller B, Tamm M: Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007, 131(1):9-19.
• [9]Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, Périat P, Bucher HC, Christ-Crain M: Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008, 168(18):2000-2007. discussion 2007–8
• [10]Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B, ProHOSP Study Group: Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 302(10):1059-1066.
• [11]Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Müller B: Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004, 363(9409):600-607.
• [12]Long W, Deng X, Zhang Y, Lu G, Xie J, Tang J: Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 2011, 16(5):819-824.
• [13]Hochreiter M, Köhler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, Schroeder S: Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009, 13(3):R83. BioMed Central Full Text
• [14]Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J: Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008, 177(5):498-505.
• [15]Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M, PRORATA trial group: Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375(9713):463-474.
• [16]Braithwaite S: Procalcitonin: new insights on regulation and origin. Crit Care Med 2000, 28(2):586-588.
• [17]Meissner M: PCT, Procalcitonin: a new, innovative infection parameter. Berlin: Brahms Diagnostica; 1996.
• [18]Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C: High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993, 341(8844):515-518.
• [19]Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Muller B: Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med 2004, 32(8):1715-1721.
• [20]Oberhoffer M, Vogelsang H, Jäger L, Reinhart K: Katacalcin and calcitonin immunoreactivity in different types of leukocytes indicate intracellular procalcitonin content. J Crit Care 1999, 14(1):29-33.
• [21]de Kruif MD, Lemaire LC, Giebelen IA, Struck J, Morgenthaler NG, Papassotiriou J, Elliott PJ, van der Poll T: The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med 2008, 34(3):518-522.
• [22]Tugrul S, Esen F, Celebi S, Ozcan PE, Akinci O, Cakar N, Telci L: Reliability of procalcitonin as a severity marker in critically ill patients with inflammatory response. Anaesth Intensive Care 2002, 30(6):747-754.
• [23]Kraft M: The role of bacterial infections in asthma. Clin Chest Med 2000, 21(2):301-313.
• [24]Gern JE, Busse WW: The role of viral infections in the natural history of asthma. J Allergy Clin Immunol 2000, 106(2):201-212.
• [25]Müller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, Nusbaumer C, Tamm M, Christ-Crain M: Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007, 7:10. BioMed Central Full Text
• [26]Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, Marsch S, Azzola A, Rakic J, Mueller B, Tamm M: Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009, 34(6):1364-1375.
• [27]Viallon A, Guyomarc'h S, Marjollet O, Berger C, Carricajo A, Robert F, Laporte S, Lambert C, Page Y, Zéni F, Bertrand JC: Can emergency physicians identify a high mortality subgroup of patients with sepsis: role of procalcitonin. Eur J Emerg Med 2008, 15(1):26-33.
• [28]Tang H, Huang T, Jing J, Shen H, Cui W: Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009, 37(6):497-507.
• [29]Abdollahi A, Shoar S, Nayyeri F, Shariat M: Diagnostic Value of Simultaneous Measurement of Procalcitonin, Interleukin-6 and hs-CRP in Prediction of Early-Onset Neonatal Sepsis. Mediterr J Hematol Infect Dis 2012, 4(1):e2012028.
• [30]Ventetuolo CE, Levy MM: Biomarkers: diagnosis and risk assessment in sepsis. Clin Chest Med 2008, 29(4):591-603.
• [31]Sutherland RE, Olsen JS, McKinstry A, Villalta SA, Wolters PJ: Mast cell IL-6 improves survival from Klebsiella pneumonia and sepsis by enhancing neutrophil killing. J Immunol 2008, 181(8):5598-5605.
• [32]Tsujimoto H, Takahata R, Nomura S, Kumano I, Matsumoto Y, Yoshida K, Hiraki S, Aosasa S, Ono S, Yamamoto J, Hase K: Predictive value of pleural and serum interleukin-6 levels for pneumonia and hypo-oxygenations after esophagectomy. J Surg Res 2013, 182(2):e61-e67.
• [33]Du B, Pan J, Chen D, Li Y: Serum procalcitonin and interleukin-6 levels may help to differentiate systemic inflammatory response of infectious and non-infectious origin. Chin Med J (Engl) 2003, 116(4):538-542.
• [34]Kraft M, Hamid Q: Mycoplasma in severe asthma. J Allergy Clin Immunol 2006, 117(5):1197-1198.
• [35]Zhang Q, Illing R, Hui CK, Downey K, Carr D, Stearn M, Alshafi K, Menzies-Gow A, Zhong N, Fan CK: Bacteria in sputum of stable severe asthma and increased airway wall thickness. Respir Res 2012, 13:35. BioMed Central Full Text